🇺🇸 FDA
Patent

US 10583180

Method for treating adenosine deaminase severe combined imunodeficiency

granted A61KA61K35/28A61K38/50

Quick answer

US patent 10583180 (Method for treating adenosine deaminase severe combined imunodeficiency) held by The Regents of the University of California expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K35/28, A61K38/50, A61K48/0008, A61K48/0066